CN103732271B - 检测和***和病毒感染等疾病的方法和装置 - Google Patents
检测和***和病毒感染等疾病的方法和装置 Download PDFInfo
- Publication number
- CN103732271B CN103732271B CN201280027324.3A CN201280027324A CN103732271B CN 103732271 B CN103732271 B CN 103732271B CN 201280027324 A CN201280027324 A CN 201280027324A CN 103732271 B CN103732271 B CN 103732271B
- Authority
- CN
- China
- Prior art keywords
- blood
- ctc
- cell
- patient
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 70
- 201000010099 disease Diseases 0.000 title abstract description 39
- 238000001514 detection method Methods 0.000 title description 9
- 208000001756 Virus Disease Diseases 0.000 title description 5
- 210000004369 Blood Anatomy 0.000 claims abstract description 555
- 239000008280 blood Substances 0.000 claims abstract description 554
- 210000002381 Plasma Anatomy 0.000 claims abstract description 147
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims abstract description 27
- 210000004027 cells Anatomy 0.000 claims description 137
- 108090001123 antibodies Proteins 0.000 claims description 134
- 102000004965 antibodies Human genes 0.000 claims description 134
- 210000004881 tumor cells Anatomy 0.000 claims description 131
- 239000000969 carrier Substances 0.000 claims description 85
- 239000003463 adsorbent Substances 0.000 claims description 81
- 239000007790 solid phase Substances 0.000 claims description 78
- 239000000835 fiber Substances 0.000 claims description 74
- 239000012528 membrane Substances 0.000 claims description 68
- 239000000427 antigen Substances 0.000 claims description 57
- 108091007172 antigens Proteins 0.000 claims description 57
- 102000038129 antigens Human genes 0.000 claims description 57
- 230000004087 circulation Effects 0.000 claims description 40
- 210000003743 Erythrocytes Anatomy 0.000 claims description 18
- 239000012510 hollow fiber Substances 0.000 claims description 15
- 210000001772 Blood Platelets Anatomy 0.000 claims description 13
- 210000003462 Veins Anatomy 0.000 claims description 12
- 239000011148 porous material Substances 0.000 claims description 12
- 101700021338 LEC Proteins 0.000 claims description 11
- 101700077545 LECC Proteins 0.000 claims description 11
- 101700028499 LECG Proteins 0.000 claims description 11
- 101700063913 LECT Proteins 0.000 claims description 11
- 101710034340 Os04g0173800 Proteins 0.000 claims description 11
- 101700036391 lecA Proteins 0.000 claims description 11
- -1 polyethylene Polymers 0.000 claims description 11
- 230000000903 blocking Effects 0.000 claims description 10
- 101710026914 AAG Proteins 0.000 claims description 9
- 101700048515 LEC1 Proteins 0.000 claims description 9
- 101700046135 LEC2 Proteins 0.000 claims description 9
- 101700028593 LECH Proteins 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 239000000910 agglutinin Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 229960002897 Heparin Drugs 0.000 claims description 7
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 7
- 229920000669 heparin Polymers 0.000 claims description 7
- 239000004698 Polyethylene (PE) Substances 0.000 claims description 5
- 229920003043 Cellulose fiber Polymers 0.000 claims description 4
- 229920002301 Cellulose acetate Polymers 0.000 claims description 3
- 102000011782 Keratins Human genes 0.000 claims description 3
- 108010076876 Keratins Proteins 0.000 claims description 3
- 239000004695 Polyether sulfone Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 229920002496 poly(ether sulfone) Polymers 0.000 claims description 2
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 claims description 2
- 102000014447 Complement C1q Human genes 0.000 claims 1
- 108010078043 Complement C1q Proteins 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 229920002492 poly(sulfones) Polymers 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 230000001717 pathogenic Effects 0.000 abstract description 120
- 244000052769 pathogens Species 0.000 abstract description 114
- 238000000338 in vitro Methods 0.000 abstract description 86
- 241000700605 Viruses Species 0.000 abstract description 74
- 230000002779 inactivation Effects 0.000 abstract description 68
- 238000000034 method Methods 0.000 abstract description 54
- 230000017531 blood circulation Effects 0.000 abstract description 42
- 238000002560 therapeutic procedure Methods 0.000 abstract description 30
- 238000002512 chemotherapy Methods 0.000 abstract description 26
- 238000001959 radiotherapy Methods 0.000 abstract description 24
- 201000009910 diseases by infectious agent Diseases 0.000 abstract description 23
- 201000011510 cancer Diseases 0.000 abstract description 20
- 230000000844 anti-bacterial Effects 0.000 abstract description 13
- 210000003850 cellular structures Anatomy 0.000 abstract description 7
- 206010003816 Autoimmune disease Diseases 0.000 abstract description 6
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 abstract description 6
- 238000000053 physical method Methods 0.000 abstract description 3
- 208000006551 Parasitic Disease Diseases 0.000 abstract description 2
- 238000000746 purification Methods 0.000 description 81
- 239000003814 drug Substances 0.000 description 77
- 230000000694 effects Effects 0.000 description 66
- 235000012489 doughnuts Nutrition 0.000 description 41
- 210000000601 Blood Cells Anatomy 0.000 description 40
- 239000000470 constituent Substances 0.000 description 36
- 241000725303 Human immunodeficiency virus Species 0.000 description 35
- 210000000265 Leukocytes Anatomy 0.000 description 33
- 239000000463 material Substances 0.000 description 33
- 239000008187 granular material Substances 0.000 description 31
- 230000027455 binding Effects 0.000 description 30
- 230000001225 therapeutic Effects 0.000 description 30
- 239000007788 liquid Substances 0.000 description 28
- 229940079593 drugs Drugs 0.000 description 27
- 239000000126 substance Substances 0.000 description 27
- 210000003677 Hemocytes Anatomy 0.000 description 26
- 239000002245 particle Substances 0.000 description 26
- 230000035700 Clearance Rate Effects 0.000 description 25
- 239000004005 microsphere Substances 0.000 description 24
- 239000010408 film Substances 0.000 description 23
- 239000003446 ligand Substances 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- 229940000351 Hemocyte Drugs 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 21
- 238000010521 absorption reaction Methods 0.000 description 20
- 239000000562 conjugate Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 102100010912 EPCAM Human genes 0.000 description 19
- 230000000875 corresponding Effects 0.000 description 19
- 230000000415 inactivating Effects 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 19
- 239000000306 component Substances 0.000 description 18
- 238000001914 filtration Methods 0.000 description 18
- 239000003504 photosensitizing agent Substances 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 231100000486 side effect Toxicity 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- 238000010168 coupling process Methods 0.000 description 17
- 238000005859 coupling reaction Methods 0.000 description 17
- 238000004140 cleaning Methods 0.000 description 16
- 230000001808 coupling Effects 0.000 description 15
- 230000001951 hemoperfusion Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- 229920002684 Sepharose Polymers 0.000 description 13
- 238000001631 haemodialysis Methods 0.000 description 13
- 229920000936 Agarose Polymers 0.000 description 12
- 108060002563 EPCAM Proteins 0.000 description 12
- 230000000322 hemodialysis Effects 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 239000003053 toxin Substances 0.000 description 12
- 241000711549 Hepacivirus C Species 0.000 description 11
- 108010028554 LDL Cholesterol Proteins 0.000 description 11
- 231100000765 Toxin Toxicity 0.000 description 11
- 230000001413 cellular Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 239000008367 deionised water Substances 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 10
- 231100000614 Poison Toxicity 0.000 description 10
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N Psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 10
- 230000002164 acetylcholinergic Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 210000002865 immune cell Anatomy 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 238000002616 plasmapheresis Methods 0.000 description 10
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- ATDGTVJJHBUTRL-UHFFFAOYSA-N Cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 8
- 229960002477 Riboflavin Drugs 0.000 description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 238000004132 cross linking Methods 0.000 description 8
- 230000002147 killing Effects 0.000 description 8
- 244000045947 parasites Species 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 229920003288 polysulfone Polymers 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 7
- 229920002395 Aptamer Polymers 0.000 description 7
- 229940088598 Enzyme Drugs 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 239000002619 cytotoxin Substances 0.000 description 7
- 239000006249 magnetic particle Substances 0.000 description 7
- 239000011976 maleic acid Substances 0.000 description 7
- 238000002428 photodynamic therapy Methods 0.000 description 7
- 239000002574 poison Substances 0.000 description 7
- 210000003370 receptor cell Anatomy 0.000 description 7
- 210000001367 Arteries Anatomy 0.000 description 6
- 229960000633 Dextran Sulfate Drugs 0.000 description 6
- 206010027476 Metastasis Diseases 0.000 description 6
- 108020004459 Small Interfering RNA Proteins 0.000 description 6
- 229930003471 Vitamin B2 Natural products 0.000 description 6
- 239000000611 antibody drug conjugate Substances 0.000 description 6
- 108091008116 antibody drug conjugates Proteins 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000002969 morbid Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 6
- 230000000717 retained Effects 0.000 description 6
- 239000002924 silencing RNA Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 230000003612 virological Effects 0.000 description 6
- 239000011716 vitamin B2 Substances 0.000 description 6
- 235000019164 vitamin B2 Nutrition 0.000 description 6
- 206010010144 Completed suicide Diseases 0.000 description 5
- 101700036477 FOLH1 Proteins 0.000 description 5
- 102100008453 FOLH1 Human genes 0.000 description 5
- 229920001503 Glucan Polymers 0.000 description 5
- 108090001030 Lipoproteins Proteins 0.000 description 5
- 102000004895 Lipoproteins Human genes 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- CXKWCBBOMKCUKX-UHFFFAOYSA-M Methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 5
- 229940042115 Methylene blue Drugs 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 125000003368 amide group Chemical group 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000002596 immunotoxin Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 229960000907 methylthioninium chloride Drugs 0.000 description 5
- 230000003287 optical Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000002271 resection Methods 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 230000002142 suicide Effects 0.000 description 5
- 101700027111 3SA0 Proteins 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 4
- 101700008337 PSMA Proteins 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 4
- 238000002679 ablation Methods 0.000 description 4
- 102000034433 acetylcholine receptors Human genes 0.000 description 4
- 108020000715 acetylcholine receptors Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012503 blood component Substances 0.000 description 4
- 238000000315 cryotherapy Methods 0.000 description 4
- 101700067609 ctx Proteins 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000001506 immunosuppresive Effects 0.000 description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 101710027066 ALB Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 210000000170 Cell Membrane Anatomy 0.000 description 3
- 206010012601 Diabetes mellitus Diseases 0.000 description 3
- 229960000304 Folic Acid Drugs 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 229940040461 Lipase Drugs 0.000 description 3
- 108020004999 Messenger RNA Proteins 0.000 description 3
- 206010028417 Myasthenia gravis Diseases 0.000 description 3
- WJFKNYWRSNBZNX-UHFFFAOYSA-N Phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 3
- 229950000688 Phenothiazine Drugs 0.000 description 3
- 108010093965 Polymyxin B Proteins 0.000 description 3
- 102100009538 TNFRSF8 Human genes 0.000 description 3
- 101710040533 TNFRSF8 Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002429 anti-coagulation Effects 0.000 description 3
- 230000000259 anti-tumor Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 230000000973 chemotherapeutic Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000001085 cytostatic Effects 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000002919 epithelial cells Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 150000004676 glycans Polymers 0.000 description 3
- 238000002615 hemofiltration Methods 0.000 description 3
- 230000003301 hydrolyzing Effects 0.000 description 3
- 230000000937 inactivator Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular Effects 0.000 description 3
- 238000002647 laser therapy Methods 0.000 description 3
- 230000001665 lethal Effects 0.000 description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 3
- 102000004882 lipase Human genes 0.000 description 3
- 108090001060 lipase Proteins 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 229920002106 messenger RNA Polymers 0.000 description 3
- 239000004531 microgranule Substances 0.000 description 3
- 229960005266 polymyxin B Drugs 0.000 description 3
- 229920000024 polymyxin B Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 230000002980 postoperative Effects 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 230000003442 weekly Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- CGIHPACLZJDCBQ-UHFFFAOYSA-N Acibenzolar Chemical compound SC(=O)C1=CC=CC2=C1SN=N2 CGIHPACLZJDCBQ-UHFFFAOYSA-N 0.000 description 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 101710029981 BLLF1 Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010013795 Brentuximab Vedotin Proteins 0.000 description 2
- 229960000455 Brentuximab vedotin Drugs 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N DATI Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 101700079760 EFCB Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101700025368 ERBB2 Proteins 0.000 description 2
- 102100016662 ERBB2 Human genes 0.000 description 2
- 101710005090 ERVFC1-1 Proteins 0.000 description 2
- 102100014722 ERVS71-1 Human genes 0.000 description 2
- 101710013371 ERVS71-1 Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 206010017758 Gastric cancer Diseases 0.000 description 2
- 102000001398 Granzymes Human genes 0.000 description 2
- 108060005986 Granzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 101710015954 HVA1 Proteins 0.000 description 2
- 208000006454 Hepatitis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- 102100013423 KRT8 Human genes 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 101700065814 LEA2 Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 229920002521 Macromolecule Polymers 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N Maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 102100005499 PTPRC Human genes 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 240000005158 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Natural products OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N Spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 2
- 210000002845 Virion Anatomy 0.000 description 2
- QXKHYNVANLEOEG-UHFFFAOYSA-N XANTHOTOXIN Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000208 anti-hepatitis Effects 0.000 description 2
- 230000000692 anti-sense Effects 0.000 description 2
- 239000003005 anticarcinogenic agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 229960000892 attapulgite Drugs 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 239000003918 blood extract Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000003040 circulating cell Anatomy 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 229910052570 clay Inorganic materials 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000002596 correlated Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000003145 cytotoxic factor Substances 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000002835 hiv fusion inhibitor Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000001573 invertase Substances 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 101700001016 mbhA Proteins 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229910052625 palygorskite Inorganic materials 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 101700016463 pls Proteins 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 229910052904 quartz Inorganic materials 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000002285 radioactive Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000001954 sterilising Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000011100 viral filtration Methods 0.000 description 2
- 210000000605 viral structures Anatomy 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000009941 weaving Methods 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2S)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- 101710037578 39 Proteins 0.000 description 1
- 229940027041 8-MOP Drugs 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 102100006669 ALPP Human genes 0.000 description 1
- 229960004373 Acetylcholine Drugs 0.000 description 1
- 108050008874 Annexins Proteins 0.000 description 1
- 102000000412 Annexins Human genes 0.000 description 1
- 229940088710 Antibiotic Drugs 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 241001249158 Artemisia verlotiorum Species 0.000 description 1
- 108060001001 BRK1 Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N Bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 208000000409 Breast Neoplasms Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 101700078950 CD44 Proteins 0.000 description 1
- 102100003735 CD44 Human genes 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920001429 Chelating resin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N Cyanogen Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N Dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 241000668709 Dipterocarpus costatus Species 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101700010580 FLO11 Proteins 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 206010018075 Generalised anxiety disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 210000003714 Granulocytes Anatomy 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010018913 Haemolysis Diseases 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- 208000002672 Hepatitis B Diseases 0.000 description 1
- 210000004299 High Vocal Center Anatomy 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 230000035809 INACTIVATION RATE Effects 0.000 description 1
- 102100013321 INSR Human genes 0.000 description 1
- 101710010714 INSR Proteins 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- 231100000608 Immunotoxin Toxicity 0.000 description 1
- 108010004484 Immunotoxins Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102100011311 KNG1 Human genes 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 229940118199 Levulan Drugs 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100006037 MUC1 Human genes 0.000 description 1
- 101700052761 MUC1 Proteins 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 210000002264 Mammary Glands, Animal Anatomy 0.000 description 1
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 229960004469 Methoxsalen Drugs 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 229920000344 Molecularly imprinted polymer Polymers 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical group CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-β-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 206010029149 Nephropathy Diseases 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N Nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108060006601 PRM1 Proteins 0.000 description 1
- 101700059076 PTPRC Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 1
- 229940109328 Photofrin Drugs 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N Phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Chemical compound C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 210000004011 Plasma Cells Anatomy 0.000 description 1
- 230000036340 Plasma Clearance Effects 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000710179 Potato virus S Species 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 210000002321 Radial Artery Anatomy 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- 102000012010 Sialomucins Human genes 0.000 description 1
- 108010061228 Sialomucins Proteins 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 206010040943 Skin ulcer Diseases 0.000 description 1
- 229920001985 Small interfering RNA Polymers 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100015249 VEGFA Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N aminolevulinic acid Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 102000025417 antigen binding proteins Human genes 0.000 description 1
- 108091000829 antigen binding proteins Proteins 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000001219 anucleate thrombocyte Anatomy 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009246 art therapy Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000002393 blood protein disease Diseases 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 230000002612 cardiopulmonary Effects 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 229960001411 chlormethine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000010559 graft polymerization reaction Methods 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical group 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid group Chemical group C(\C=C/C(=O)O)(=O)O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 101710031899 moon Proteins 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 238000009376 nuclear reprocessing Methods 0.000 description 1
- 230000021603 oncosis Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- IWQPFENGXVKSDO-UHFFFAOYSA-N phenol;2H-thiazine Chemical compound N1SC=CC=C1.OC1=CC=CC=C1 IWQPFENGXVKSDO-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000003211 photoinitiator Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- FSDZFXDDKLLPRB-UHFFFAOYSA-N phthalic acid;sulfuric acid Chemical compound OS(O)(=O)=O.OC(=O)C1=CC=CC=C1C(O)=O FSDZFXDDKLLPRB-UHFFFAOYSA-N 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000069 poly(p-phenylene sulfide) Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000002367 primary immunodeficiency disease Diseases 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000036633 rest Effects 0.000 description 1
- 230000000630 rising Effects 0.000 description 1
- 230000002000 scavenging Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing Effects 0.000 description 1
- 231100000202 sensitizing Toxicity 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000003068 static Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 101700042113 tap Proteins 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 239000001016 thiazine dye Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Abstract
Description
Claims (4)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161516956P | 2011-04-12 | 2011-04-12 | |
US61/516,956 | 2011-04-12 | ||
US201161457807P | 2011-06-08 | 2011-06-08 | |
US61/457,807 | 2011-06-08 | ||
PCT/US2012/033153 WO2012142180A1 (en) | 2011-04-12 | 2012-04-11 | Methods to detect and treat diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103732271A CN103732271A (zh) | 2014-04-16 |
CN103732271B true CN103732271B (zh) | 2016-11-30 |
Family
ID=
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4215688A (en) * | 1979-02-09 | 1980-08-05 | Baxter Travenol Laboratories, Inc. | Apparatus for the extracorporeal treatment of disease |
CN2058851U (zh) * | 1989-10-15 | 1990-07-04 | 王万林 | 自体血紫外线照射、充氧处理装置 |
US5871649A (en) * | 1996-06-20 | 1999-02-16 | Baxter International Inc. | Affinity membrane system and method of using same |
CN1565654A (zh) * | 2003-07-03 | 2005-01-19 | 北京京精医疗设备有限公司 | 体外循环血液中病毒灭活方法及其应用 |
CN1741822A (zh) * | 2002-11-04 | 2006-03-01 | 阿什兰公司 | 利用超声波处理液体介质以防止过度增殖或感染细胞生长的设备与方法 |
CN101370536A (zh) * | 2005-12-13 | 2009-02-18 | 埃克塞拉有限责任公司 | 用于从血液中体外去除病原微生物、炎性细胞或炎性蛋白质的方法 |
CN101878429A (zh) * | 2007-11-27 | 2010-11-03 | 维里德克斯有限责任公司 | 血液中循环黑素瘤细胞的自动化计数和表征 |
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4215688A (en) * | 1979-02-09 | 1980-08-05 | Baxter Travenol Laboratories, Inc. | Apparatus for the extracorporeal treatment of disease |
CN2058851U (zh) * | 1989-10-15 | 1990-07-04 | 王万林 | 自体血紫外线照射、充氧处理装置 |
US5871649A (en) * | 1996-06-20 | 1999-02-16 | Baxter International Inc. | Affinity membrane system and method of using same |
CN1741822A (zh) * | 2002-11-04 | 2006-03-01 | 阿什兰公司 | 利用超声波处理液体介质以防止过度增殖或感染细胞生长的设备与方法 |
CN1565654A (zh) * | 2003-07-03 | 2005-01-19 | 北京京精医疗设备有限公司 | 体外循环血液中病毒灭活方法及其应用 |
CN101370536A (zh) * | 2005-12-13 | 2009-02-18 | 埃克塞拉有限责任公司 | 用于从血液中体外去除病原微生物、炎性细胞或炎性蛋白质的方法 |
CN101878429A (zh) * | 2007-11-27 | 2010-11-03 | 维里德克斯有限责任公司 | 血液中循环黑素瘤细胞的自动化计数和表征 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20150283318A1 (en) | Methods to detect and treat diseases | |
US20130131423A1 (en) | Methods to detect and treat diseases | |
CN1980696B (zh) | 除去病人体内可溶性tnfr1,tnfr2和il2的方法和*** | |
CN102791307B (zh) | 通过体外疗法除去毒力因子 | |
CN106267422B (zh) | Rh血型不合溶血病治疗仪 | |
CN102600521A (zh) | 一种清除血液中病原体的装置和方法 | |
WO2011163533A2 (en) | One step removal of selected molecules from body fluid and tissue | |
JP4495258B2 (ja) | 物質の供給および除去のための相互作用システム | |
WO2006012885A1 (de) | Filtersystem zur membrangetrennten, adsorptiven behandlung partikelhaltiger flüssigkeiten | |
CN106267407B (zh) | 母胎Rh血型不合血液净化治疗仪 | |
CN106110423B (zh) | 母胎血型不合吸附治疗仪 | |
CN106267410B (zh) | 艾滋病感染细胞分离器 | |
CN103732271B (zh) | 检测和***和病毒感染等疾病的方法和装置 | |
CN106344986B (zh) | 母胎血型不合治疗吸附器 | |
CN106267405B (zh) | 母胎血型不合溶血病治疗仪 | |
CN102319439B (zh) | 一种带磁性微球的药物及用途 | |
KR100978169B1 (ko) | 면역 억제 물질 흡착재, 체외 순환 컬럼 및 암의 치료방법 | |
CN106178162B (zh) | 艾滋病治疗细胞器 | |
CN106267411B (zh) | 艾滋病排毒治疗仪 | |
CN106267420B (zh) | Hiv吞噬细胞器 | |
CN106267404B (zh) | 艾滋病生物细胞治疗仪 | |
CN106110422A (zh) | 艾滋病免疫治疗吸附器 | |
JPH0316639A (ja) | 吸着体およびそれを用いた除去装置 | |
JPS5949773A (ja) | 生物特異性重合物 | |
JPH01294637A (ja) | 免疫抗体、補体の採取法と採取装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Tianxin Inventor after: Liu Lei Inventor before: Wang Tianxin Inventor before: Ma Wenbin Inventor before: Chen Yiwang Inventor before: Liu Lei |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20160713 Address after: American California Applicant after: Wang Tianxin Applicant after: Liu Lei Address before: American California Applicant before: Wang Tianxin Applicant before: Ma Wenbin Applicant before: Chen Yiwang Applicant before: Liu Lei |
|
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161130 Termination date: 20190411 |